Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio per valutare la sicurezza, la farmacocinetica e l'efficacia preliminare della terapia IDE574 in partecipanti adulti con tumori solidi avanzati

2 novembre 2026 aggiornato da: IDEAYA Biosciences

An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic Cancer

IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.

The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic cancer.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Descrizione dettagliata

Part 1 - Monotherapy Dose Escalation and Expansion:

Part 1A - Monotherapy Dose Escalation Part 1A will evaluate increasing doses of IDE574 to assess safety, tolerability and to determine dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) or the recommended dose for expansion (RDE) in subjects with advanced or metastatic cancer.

Part 1B - Monotherapy Dose Expansion Part 1B will evaluate in ER+ HER2- advanced or metastatic cancer at one RDE determined from Part 1A or the MTD.

Part 1C - Exploratory Food Effect Sub-study

Part 2 - Combination Dose Escalation and Expansion

Part 2A - IDE574 Combination Therapy with Fulvestrant Dose Escalation Part 2A will evaluate participants with advanced or metastatic cancer with escalating doses of IDE574 in combination with fulvestrant to assess safety, tolerability and to determine DLTs, MTD or RDE.

Part 2B - IDE574 Combination Therapy with Fulvestrant Dose Expansion Part 2B will randomly assign participants with advanced or metastatic cancer to dose levels selected from Part 2A

Tipo di studio

Interventistico

Iscrizione (Stimato)

155

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • K'alak'i T'bilisi
      • Batumi, K'alak'i T'bilisi, Georgia, 6000
        • Reclutamento
        • High Technology Hospital MedCenter Ltd
        • Investigatore principale:
          • Tamta Makharadze, MD
        • Contatto:
      • Tbilisi, K'alak'i T'bilisi, Georgia, 114
        • Reclutamento
        • Pineo Medical Ecosystem
        • Contatto:
        • Investigatore principale:
          • Mziuri Zakaraia, MD
      • Tbilisi, K'alak'i T'bilisi, Georgia, 112
        • Attivo, non reclutante
        • LLC ARENSIA Exploratory Medicine
      • Tbilisi, K'alak'i T'bilisi, Georgia, 144
        • Attivo, non reclutante
        • Geo Hospitals Multiprofile Medical Center Tbilisi
      • Tbilisi, K'alak'i T'bilisi, Georgia, 186
        • Attivo, non reclutante
        • LLC Caucasus Medical Centre
    • California
      • Santa Monica, California, Stati Uniti, 90404-2095
        • Attivo, non reclutante
        • UCLA - Parkside Cancer Center
    • Connecticut
      • New Haven, Connecticut, Stati Uniti, 06510-3206
        • Reclutamento
        • Yale School of Medicine - Cedar Street
        • Investigatore principale:
          • Patricia LoRusso, MD
        • Contatto:
    • Florida
      • Plantation, Florida, Stati Uniti, 33322
        • Reclutamento
        • Florida Clinical Trials Group
        • Investigatore principale:
          • Harshad Amin, MD
        • Contatto:
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322-1013
        • Reclutamento
        • Winship Cancer Institute, Emory University
        • Investigatore principale:
          • Shipra Gandhi, MD
        • Contatto:
    • Missouri
      • St Louis, Missouri, Stati Uniti, 63110-1010
        • Reclutamento
        • Washington University - Siteman Cancer Center
        • Investigatore principale:
          • Faisal Fa'ak, MD
        • Contatto:
    • New Jersey
      • East Brunswick, New Jersey, Stati Uniti, 08816
        • Reclutamento
        • START Astera, LLC
        • Investigatore principale:
          • Bruno Fang, MD
        • Contatto:
    • New York
      • Lake Success, New York, Stati Uniti, 11042
        • Reclutamento
        • START New York Long Island, LLC
        • Investigatore principale:
          • Geraldine O'Sullivan Coyne, MD
        • Contatto:
      • New York, New York, Stati Uniti, 10032-3729
        • Attivo, non reclutante
        • Columbia University Medical Center -161 Fort Washington
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37203
        • Reclutamento
        • SCRI Oncology Partners - PPDS
        • Investigatore principale:
          • Sarah Premji, MD
        • Contatto:
    • Texas
      • Austin, Texas, Stati Uniti, 78758
        • Reclutamento
        • NEXT Texas LLC - Austin
        • Investigatore principale:
          • Sheena Sahota, MD
        • Contatto:
      • Dallas, Texas, Stati Uniti, 75039
        • Reclutamento
        • NEXT Texas LLC - Dallas
        • Investigatore principale:
          • Faran Polani, MD
        • Contatto:
      • Fort Worth, Texas, Stati Uniti, 76104
        • Reclutamento
        • START Dallas Fort Worth, LLC
        • Investigatore principale:
          • Henry Xiong, MD
        • Contatto:
      • Houston, Texas, Stati Uniti, 77030-4009
        • Reclutamento
        • MD Anderson Cancer Center
        • Investigatore principale:
          • Timothy Yap, MD
        • Contatto:
      • Houston, Texas, Stati Uniti, 77054
        • Reclutamento
        • NEXT Texas LLC - Houston
        • Investigatore principale:
          • Jennifer Segar, MD
        • Contatto:
      • San Antonio, Texas, Stati Uniti, 78229
        • Reclutamento
        • NEXT Texas LLC - San Antonio
        • Investigatore principale:
          • David Sommerhalder, MD
        • Contatto:
      • San Antonio, Texas, Stati Uniti, 78229
        • Reclutamento
        • Start San Antonio, LLC
        • Investigatore principale:
          • Amita Patnaik, MD
        • Contatto:
    • Utah
      • West Valley City, Utah, Stati Uniti, 84119
        • Reclutamento
        • START Mountain Region, LLC
        • Investigatore principale:
          • William McKean, MD
        • Contatto:
    • Virginia
      • Fairfax, Virginia, Stati Uniti, 22031
        • Reclutamento
        • NEXT Virginia
        • Investigatore principale:
          • Mohamad Salkeni, MD
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 99 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

Archival Tissue sample for testing

  • Part 1A - Participants with advanced or metastatic cancer who have progressed on/after standard of care therapy or are intolerant to additional effective therapies.
  • Female participants with cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause (Parts 2A and B only)
  • Female participants of nonchildbearing potential with cancer must meet at least 1 of the following criteria: Age ≥ 60 years or age <60 years with absence of menstruation for at least 12 months, or had prior removal of both ovaries
  • Have Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1.
  • Have adequate bone marrow, renal and liver function.
  • Life expectancy of >3 months
  • Able to safely administer and retain orally administered study treatment
  • Able to comply with contraceptive/barrier requirements

Key Exclusion Criteria:

  • Known symptomatic brain metastases or leptomeningeal metastasis
  • Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose with the exception of adequately treated localized tumor.
  • Have impairment of GI function or GI disease that may significantly alter the absorption of IDE574.
  • Have active liver or biliary disease.
  • Have active, uncontrolled bacterial, fungal, or viral infection
  • Have clinically significant cardiac abnormalities and/or blood clotting events within 6 months before the first dose
  • If participants had adverse reactions to previous experimental antitumor treatment that have not recovered to Grade ≤ 1
  • Prior irradiation to >25% of the bone marrow.
  • Known or suspected hypersensitivity to IDE574/excipients or components (Parts 1 & 2) or fulvestrant/excipients or components (Part 2 only)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Monotherapy Dose Escalation (Part 1A)

Participants with the appropriate tumor types will be treated with escalating doses of IDE574

IDE574

Sperimentale: Monotherapy Dose Expansion (Part 1B)

Participants with advanced or metastatic cancer will be treated using the RDE or MTD of IDE574

IDE574

Sperimentale: Combination Dose Escalation (Part 2A) IDE574 + Fulvestrant

Participants with advanced or metastatic cancer will be treated with escalating doses of IDE574 in combination with fulvestrant

IDE574

Fulvestrant Injection

Sperimentale: Combination Dose Expansion (Part 2B)

Participants with advanced or metastatic cancer will be randomly assigned to doses of IDE574 + Fulvestrant

IDE574

Fulvestrant Injection

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation
Lasso di tempo: Following the first dose of IDE574

incidence of DLT; incidence and severity of AEs/serious adverse events (SAEs) graded based on CTCAE V6.0

Following the first dose of IDE574
Safety and Tolerability of IDE574 in Part 1B Monotherapy Dose expansion based on incidence and severity of AEs/SAEs
Lasso di tempo: total study duration

Incidence and severity of AEs/SAEs graded based on CTCAE V6.0

total study duration
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on the ORR per RECIST version 1.1
Lasso di tempo: total study duration

Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on DOR per RECIST version 1.1.
Lasso di tempo: total study duration

Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2A Combination Dose Escalation based on incidence of DLT
Lasso di tempo: total study duration

Incidence of DLT; incidence and severity of AEs/SAEs graded based on CTCAE V6.0

total study duration
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the incidence and severity of AEs/SAEs
Lasso di tempo: total study duration

Incidence and severity of AEs/SAEs graded based on CTCAE V6.0

total study duration
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the ORR per RECIST version 1.1
Lasso di tempo: total study duration

Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on DOR per RECIST version 1.1.
Lasso di tempo: total study duration

Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration

Misure di risultato secondarie

Misura del risultato
Lasso di tempo
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on the ORR per RECIST version 1.1
Lasso di tempo: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on DOR per RECIST version 1.1.
Lasso di tempo: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Clinical Benefit Rate (CBR)
Lasso di tempo: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Disease control rate
Lasso di tempo: total study duration
total study duration
Evaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose Escalation
Lasso di tempo: total study duration
total study duration
Evaluate the PK of IDE574 in Part 1B Monotherapy Dose Expansion
Lasso di tempo: total study duration
total study duration
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion
Lasso di tempo: total study duration
total study duration
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on DCR for other solid tumor types
Lasso di tempo: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on ORR per RECIST version 1.1
Lasso di tempo: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on DOR per RECIST version 1.1
Lasso di tempo: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on CBR per RECIST version 1.1
Lasso di tempo: total study duration
total study duration
Evaluate the PK of IDE574 in Part 2A Combination Dose Escalation
Lasso di tempo: total study duration
total study duration
Evaluate antitumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on CBR per RECIST version 1.1
Lasso di tempo: total study duration
total study duration
Evaluate the PK of IDE574 in Part 2B Combination Dose Expansion
Lasso di tempo: total study duration
total study duration

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

17 marzo 2026

Completamento primario (Stimato)

31 dicembre 2029

Completamento dello studio (Stimato)

31 gennaio 2030

Date di iscrizione allo studio

Primo inviato

1 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

14 aprile 2026

Primo Inserito (Effettivo)

20 aprile 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

2 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • IDE574-001
  • 178299 (Altro identificatore: Regulatory Agency Identifier Number (s))

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi